Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|
Unadjusted OR (95% CI) | P | Adjusted OR (95% CI) | P | |
Male | 0.444 (0.211–0.934) | 0.032 | ||
Ages | 1.129 (1.048–1.216) | 0.001 | 1.112 (1.020–1.212) | 0.016 |
Body mass index | 0.969 (0.878–1.070) | 0.537 | ||
Hypertension | 0.798 (0.392–1.627) | 0.535 | ||
Diabetes mellitus | 0.535 (0.582–2.837) | 0.535 | ||
Ischemic heart diseases | 1.120 (0.493–2.547) | 0.787 | ||
Congestive heart diseases | 1.871 (0.415–8.428) | 0.734 | ||
Cerebrovascular diseases | 0.858 (0.323–2.281) | 0.759 | ||
COPD | 3.419 (0.718–16.285) | 0.311 | ||
Solid malignancy | 0.711 (0.338–1.495) | 0.366 | ||
Serum hemoglobin | 0.988 (0.969–1.006) | 0.193 | ||
Serum albumin | 0.863 (0.802–0.929) | < 0.001 | 0.900 (0.829–0.977) | 0.012 |
Alanine aminotransferase | 1.004 (1.001–1.007) | 0.024 | ||
Aspartate aminotransferase | 1.003 (1.000–1.005) | 0.037 | ||
Baseline eGFR (mL/min/1.73 m2) < 60 | 6.544 (3.137–13.649) | < 0.001 | 3.401 (1.479–7.820) | 0.004 |
ASA score | 3.063 (1.584–5.923) | 0.001 | ||
Charlson score | 1.203 (1.035–1.399) | 0.071 | ||
RCRI score | 1.895 (1.204–2.981) | 0.005 | ||
Non-renal RCRI score | 1.654 (1.034–2.645) | 0.033 | ||
Surgical approach(Laparoscopic) | 0.623 (0.294–1.319) | 0.213 | ||
Intraoperative characteristics | ||||
Duration of anesthesia | 1.000 (0.997–1.003) | 0.850 | ||
Operative time | 1.000 (0.996–1.003) | 0.933 | ||
IOH | 4.141 (2.023–8.477) | < 0.001 | 3.509 (1.553–7.929) | 0.003 |
Amount of crystalloids use | 1.000 (0.999–1.001) | 0.476 | ||
Blood loss | 0.999 (0.995–1.002) | 0.465 | ||
Vasoactive drug use | 0.783 (0.330–1.857) | 0.578 | ||
Usage of nephrotoxic drugs | ||||
Hydroxyethyl starch | 0.292 (0.111–0.768) | 0.008 | ||
NSAID | 0.413 (0.097–1.761) | 0.333 | ||
Hydroxyethyl starch + NSAID | 2.896 (1.375–6.098) | 0.004 | 3.596 (1.559–8.292) | 0.003 |
Hydroxyethyl starch + furosemide | 11.875 (3.648–38.654) | < 0.001 | 5.724 (1.476–22.199) | 0.012 |